Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab

T. Bongartz, P. Härle, S. Friedrich, S. Karrer, T. Vogt, A. Seitz, U. Müller-Ladner

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Psoriatic onycho-pachydermo periostitis (POPP) is recognized as a rare subset of psoriatic arthritis, characterized by psoriatic onychodystrophy, connective tissue thickening above the distal phalanx, and a periosteal reaction. Therapy for this rare disease is based on treatments used for psoriatic arthritis, but traditional disease-modifying antirheumatic drugs, such as sulfasalazine and methotrexate, have shown inconsistent and unsatisfactory results. We report herein a successful therapeutic approach for POPP using the fully human anti-tumor necrosis factor (TNF) antibody adalimumab in a 42-year-old male patient. After 4 months of anti-TNF treatment, a remarkable normalization of the clinical appearance was achieved and magnetic resonance imaging showed complete resolution of the initial inflammatory lesions. Therefore, we consider a TNF-blocking strategy as promising for treatment of POPP.

Original languageEnglish (US)
Pages (from-to)280-282
Number of pages3
JournalArthritis and Rheumatism
Volume52
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Periostitis
Psoriatic Arthritis
Tumor Necrosis Factor-alpha
Therapeutics
Sulfasalazine
Antirheumatic Agents
Rare Diseases
Methotrexate
Connective Tissue
Magnetic Resonance Imaging
Adalimumab
Antibodies

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Bongartz, T., Härle, P., Friedrich, S., Karrer, S., Vogt, T., Seitz, A., & Müller-Ladner, U. (2005). Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. Arthritis and Rheumatism, 52(1), 280-282. https://doi.org/10.1002/art.20763

Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. / Bongartz, T.; Härle, P.; Friedrich, S.; Karrer, S.; Vogt, T.; Seitz, A.; Müller-Ladner, U.

In: Arthritis and Rheumatism, Vol. 52, No. 1, 01.2005, p. 280-282.

Research output: Contribution to journalArticle

Bongartz, T, Härle, P, Friedrich, S, Karrer, S, Vogt, T, Seitz, A & Müller-Ladner, U 2005, 'Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab', Arthritis and Rheumatism, vol. 52, no. 1, pp. 280-282. https://doi.org/10.1002/art.20763
Bongartz T, Härle P, Friedrich S, Karrer S, Vogt T, Seitz A et al. Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. Arthritis and Rheumatism. 2005 Jan;52(1):280-282. https://doi.org/10.1002/art.20763
Bongartz, T. ; Härle, P. ; Friedrich, S. ; Karrer, S. ; Vogt, T. ; Seitz, A. ; Müller-Ladner, U. / Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. In: Arthritis and Rheumatism. 2005 ; Vol. 52, No. 1. pp. 280-282.
@article{48de6e8a679c426290efd754a4cc6ed1,
title = "Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab",
abstract = "Psoriatic onycho-pachydermo periostitis (POPP) is recognized as a rare subset of psoriatic arthritis, characterized by psoriatic onychodystrophy, connective tissue thickening above the distal phalanx, and a periosteal reaction. Therapy for this rare disease is based on treatments used for psoriatic arthritis, but traditional disease-modifying antirheumatic drugs, such as sulfasalazine and methotrexate, have shown inconsistent and unsatisfactory results. We report herein a successful therapeutic approach for POPP using the fully human anti-tumor necrosis factor (TNF) antibody adalimumab in a 42-year-old male patient. After 4 months of anti-TNF treatment, a remarkable normalization of the clinical appearance was achieved and magnetic resonance imaging showed complete resolution of the initial inflammatory lesions. Therefore, we consider a TNF-blocking strategy as promising for treatment of POPP.",
author = "T. Bongartz and P. H{\"a}rle and S. Friedrich and S. Karrer and T. Vogt and A. Seitz and U. M{\"u}ller-Ladner",
year = "2005",
month = "1",
doi = "10.1002/art.20763",
language = "English (US)",
volume = "52",
pages = "280--282",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab

AU - Bongartz, T.

AU - Härle, P.

AU - Friedrich, S.

AU - Karrer, S.

AU - Vogt, T.

AU - Seitz, A.

AU - Müller-Ladner, U.

PY - 2005/1

Y1 - 2005/1

N2 - Psoriatic onycho-pachydermo periostitis (POPP) is recognized as a rare subset of psoriatic arthritis, characterized by psoriatic onychodystrophy, connective tissue thickening above the distal phalanx, and a periosteal reaction. Therapy for this rare disease is based on treatments used for psoriatic arthritis, but traditional disease-modifying antirheumatic drugs, such as sulfasalazine and methotrexate, have shown inconsistent and unsatisfactory results. We report herein a successful therapeutic approach for POPP using the fully human anti-tumor necrosis factor (TNF) antibody adalimumab in a 42-year-old male patient. After 4 months of anti-TNF treatment, a remarkable normalization of the clinical appearance was achieved and magnetic resonance imaging showed complete resolution of the initial inflammatory lesions. Therefore, we consider a TNF-blocking strategy as promising for treatment of POPP.

AB - Psoriatic onycho-pachydermo periostitis (POPP) is recognized as a rare subset of psoriatic arthritis, characterized by psoriatic onychodystrophy, connective tissue thickening above the distal phalanx, and a periosteal reaction. Therapy for this rare disease is based on treatments used for psoriatic arthritis, but traditional disease-modifying antirheumatic drugs, such as sulfasalazine and methotrexate, have shown inconsistent and unsatisfactory results. We report herein a successful therapeutic approach for POPP using the fully human anti-tumor necrosis factor (TNF) antibody adalimumab in a 42-year-old male patient. After 4 months of anti-TNF treatment, a remarkable normalization of the clinical appearance was achieved and magnetic resonance imaging showed complete resolution of the initial inflammatory lesions. Therefore, we consider a TNF-blocking strategy as promising for treatment of POPP.

UR - http://www.scopus.com/inward/record.url?scp=12344259371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12344259371&partnerID=8YFLogxK

U2 - 10.1002/art.20763

DO - 10.1002/art.20763

M3 - Article

C2 - 15641098

AN - SCOPUS:12344259371

VL - 52

SP - 280

EP - 282

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 1

ER -